Efficacy and safety of galantamine in patients with dementia with Lewy bodies

A 12-week interim analysis

Keith R. Edwards, Linda Hershey, Laura Wray, Edward M. Bednarczyk, David Lichter, Martin Farlow, Stewart Johnson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12) improved (decreased) by 7.52 points over the 12 weeks (marginally significant, p = 0.061). NPI-12 scores decreased by half in 12 of the 25 patients. Highly significant improvement was observed in scores on the NPI-4 subscale (delusions, hallucinations, apathy, and depression: p = 0.003). Scores on the Clinician's Global Impression of Change (CGIC) improved by 0.95 points (significant, p = 0.02). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event was recorded, but it was judged to be unrelated to the study medication.

Original languageEnglish
Pages (from-to)40-48
Number of pages9
JournalDementia and Geriatric Cognitive Disorders
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - 2004

Fingerprint

Galantamine
Lewy Body Disease
compound A 12
Safety
Cholinesterase Inhibitors
Neurochemistry
Apathy
Confusion
Delusions
Hallucinations
Anorexia
Activities of Daily Living
Nausea
Sleep
Depression
Equipment and Supplies

Keywords

  • Cholinesterase inhibitors
  • Dementia with Lewy bodies (DLB)
  • Galantamine
  • Treatment

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Efficacy and safety of galantamine in patients with dementia with Lewy bodies : A 12-week interim analysis. / Edwards, Keith R.; Hershey, Linda; Wray, Laura; Bednarczyk, Edward M.; Lichter, David; Farlow, Martin; Johnson, Stewart.

In: Dementia and Geriatric Cognitive Disorders, Vol. 17, No. SUPPL. 1, 2004, p. 40-48.

Research output: Contribution to journalArticle

Edwards, Keith R. ; Hershey, Linda ; Wray, Laura ; Bednarczyk, Edward M. ; Lichter, David ; Farlow, Martin ; Johnson, Stewart. / Efficacy and safety of galantamine in patients with dementia with Lewy bodies : A 12-week interim analysis. In: Dementia and Geriatric Cognitive Disorders. 2004 ; Vol. 17, No. SUPPL. 1. pp. 40-48.
@article{4cdedc0800a34324a2f993082c2a04aa,
title = "Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis",
abstract = "Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12) improved (decreased) by 7.52 points over the 12 weeks (marginally significant, p = 0.061). NPI-12 scores decreased by half in 12 of the 25 patients. Highly significant improvement was observed in scores on the NPI-4 subscale (delusions, hallucinations, apathy, and depression: p = 0.003). Scores on the Clinician's Global Impression of Change (CGIC) improved by 0.95 points (significant, p = 0.02). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event was recorded, but it was judged to be unrelated to the study medication.",
keywords = "Cholinesterase inhibitors, Dementia with Lewy bodies (DLB), Galantamine, Treatment",
author = "Edwards, {Keith R.} and Linda Hershey and Laura Wray and Bednarczyk, {Edward M.} and David Lichter and Martin Farlow and Stewart Johnson",
year = "2004",
doi = "10.1159/000074681",
language = "English",
volume = "17",
pages = "40--48",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Efficacy and safety of galantamine in patients with dementia with Lewy bodies

T2 - A 12-week interim analysis

AU - Edwards, Keith R.

AU - Hershey, Linda

AU - Wray, Laura

AU - Bednarczyk, Edward M.

AU - Lichter, David

AU - Farlow, Martin

AU - Johnson, Stewart

PY - 2004

Y1 - 2004

N2 - Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12) improved (decreased) by 7.52 points over the 12 weeks (marginally significant, p = 0.061). NPI-12 scores decreased by half in 12 of the 25 patients. Highly significant improvement was observed in scores on the NPI-4 subscale (delusions, hallucinations, apathy, and depression: p = 0.003). Scores on the Clinician's Global Impression of Change (CGIC) improved by 0.95 points (significant, p = 0.02). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event was recorded, but it was judged to be unrelated to the study medication.

AB - Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12) improved (decreased) by 7.52 points over the 12 weeks (marginally significant, p = 0.061). NPI-12 scores decreased by half in 12 of the 25 patients. Highly significant improvement was observed in scores on the NPI-4 subscale (delusions, hallucinations, apathy, and depression: p = 0.003). Scores on the Clinician's Global Impression of Change (CGIC) improved by 0.95 points (significant, p = 0.02). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event was recorded, but it was judged to be unrelated to the study medication.

KW - Cholinesterase inhibitors

KW - Dementia with Lewy bodies (DLB)

KW - Galantamine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0346749726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346749726&partnerID=8YFLogxK

U2 - 10.1159/000074681

DO - 10.1159/000074681

M3 - Article

VL - 17

SP - 40

EP - 48

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - SUPPL. 1

ER -